Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Akio Koyama1*, Toshiro Fujita2, Fumitake Gejyo3, Hideki Origasa4, Masanao Isono5, Hajimu Kurumatani5, Kiyonobu Okada5, Hiroyuki Kanoh6, Takashi Kiriyama6 and Shunsuke Yamada6

Abstract

Background: Evidence increasingly points to the importance of chronic hypoxia in the tubulointerstitium as a final common pathway to end-stage renal disease (ESRD). Beraprost sodium (BPS) is an orally active prostacyclin (PGI₂) analogue demonstrating prevention of the progression of chronic kidney disease (CKD) in various animal models by maintaining renal blood flow and attenuating renal ischemic condition.

Methods: This multicenter, randomized, double-blind, placebo-controlled, phase II trial was designed to determine the recommended dose of the sustained-release form of BPS (TRK-100STP 120 µg/day or 240 µg/day) in Japanese patients with CKD. TRK-100STP was administered to a total of 112 patients. The primary efficacy endpoint was the difference in the slope of the regression line of reciprocal of serum creatinine (1/SCr) over time, obtained by the least-squares method.

Results: Regarding the primary endpoint, statistical superiority of TRK-100STP 240 µg over placebo was not confirmed and so a recommended dose was not determined. Compared to placebo, however, the slope of regression line of 1/SCr, elevation of SCr and serum cystatin C during the treatment period revealed greater improvement at 120 µg, at both doses, and at 240 µg, respectively. In terms of safety, both TRK-100STP treatment groups were well tolerated.

Conclusions: Although the study failed to meet the primary endpoint, results indicate that TRK-100STP may potentially prevent the decline in renal function of CKD patients independent of blood pressure or urinary protein levels.

Trial registration: NCT02480751. June 21, 2015.

Keywords: Beraprost sodium, Prostacyclin analogue, CKD, TRK-100STP, Phase II trial

Background

An increasing number of patients with end-stage renal disease (ESRD) require dialysis or transplantation. Although diabetic nephropathy is a major reason for eventual ESRD, primary glomerular diseases and nephrosclerosis still comprise significant proportions of chronic kidney disease (CKD) patients, especially in Asian countries [1–4].

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) are often administered to both diabetic and non-diabetic nephropathy patients, and are established as recommended treatment agents for non-diabetic nephropathy patients with albumin excretion [5]. However, it is evident that these agents are insufficient for the prevention of progressive renal disease. In addition, the use of combination therapy of renin-angiotensin system (RAS) inhibitors such as ACEI and ARB has demonstrated in some recent clinical trials to be not effective [6–9]. These findings suggest an urgent
clinical need for a new treatment option able to significantly delay the progression of CKD.

Prostacyclin (PGI$_2$) is primarily synthesized in endothelial cells and one of the important functions is to protect kidneys from ischemic damage in pathophysiological conditions [10], as evidenced, for example, by the development of renal impairment in prostacyclin synthase knockout mice [11]. Attempts have been made to use PGI$_2$ or its analogues in patients with kidney disease; the PGI$_2$ analogue iloprost was successfully used for patients with contrast media-induced nephropathy [12].

Beraprost sodium (BPS) is an orally active PGI$_2$ analogue [13] and TRK-100STP is its sustained-release form [14]; both were generated and developed by Toray Industries, Inc. In Asian countries, the immediate-release form of BPS has been widely used in the treatment of patients with chronic arterial occlusion and pulmonary arterial hypertension [15].

Recent evidence increasingly points to the importance of chronic hypoxia especially in the tubulointerstitium as a final common pathway to the progression of CKD [16–20]. BPS prevents the progression of CKD in various animal models [21–24] by maintaining renal microvasculature and blood flow [25, 26]. In addition, it is reported that BPS is effective in Acute Kidney Injury such as contrast nephropathy and cisplatin nephropathy [27, 28]. These effects of BPS are thought to be based on multiple mechanisms of actions: direct protective effect on vascular endothelial cells [29]; inhibition of the production of inflammatory cytokines from monocyte/macrophages [23]; vasodilative [30] and antiplatelet effects [31]. The effects of BPS have also been assessed in two studies in patients with glomerulonephritis [32, 33]. Although these studies were open-label and did not have control group, the results of one study suggested that BPS mitigates the progression rate of renal dysfunction [32, 33] by increasing renal blood flow without glomerular hyperfiltration.

The efficacy of BPS on diabetic nephropathy has also been reported in several clinical [34] and non-clinical studies [35–37]; however, several methodological limitations are evident with regards to the involvement of both diabetic and non-diabetic CKD patients in a single protocol. Given the evident unmet need for non-diabetic nephropathy treatment in Asia and considering that much of the non-clinical data on BPS has been generated in non-diabetic CKD, the priority and focus of the present study was on non-diabetic CKD, given that renal disorders are not modified by diabetes. This is the first randomized, placebo-controlled, double-blind, comparative trial to investigate the recommended dose at which TRK-100STP suppresses the progression of CKD in patients with primary glomerular disease or nephrosclerosis.

Methods
This multicenter, randomized, double-blind placebo-controlled, phase II trial was designed to determine the recommended dose of TRK-100STP (i.e., either 120 μg/day or 240 μg/day) for suppressing progression in Japanese patients with primary glomerular disease or nephrosclerosis. The study was approved by each participating center’s local Research Ethics Committee. Only patients with written informed consent were included (Please refer to the list of participating centers at the end of the paper).

Study design
A summary of the study method is presented in Fig. 1. After the run-in period, when placebo tablets were orally...
Inclusion criteria

Patients with chronic renal failure associated with primary glomerular disease or nephrosclerosis who met the following criteria were included.

At the time of pre-registration:
1. Patients between 20 and 79 years of age at the time of consent.
2. Patients who gave written consent.
3. Patients with progressive chronic kidney disease (as a general rule, patients with reciprocal of serum creatinine [1/Scr] versus time slope was ≤-0.005 dl/mg over 4 weeks were selected using all Scr data collected within one year before obtaining consent. The slope of the regression line was calculated for each patient by applying the least-squares equation).

At the time of registration
4. Patients with Ccr (urinalysis with 24-hour pooled urine samples) at Week 20 (R20) of the run-in period exceeding 15.0 ml/min.
5. Patients with SCR at Week 20 (R20) of the run-in period between 1.30-4.00 mg/dl for women and 1.50-4.50 mg/dl for men.
6. Patients with SCR versus time slope was ≤-0.005 dl/mg over 4 weeks calculated from all SCR data collected up to Week 20 (R20) of the run-in period. The slope of the regression line was calculated for each patient by applying the least-squares equation.
7. Patients with measures of SCR levels up until Week 20 (R20) of the run-in period between 50-200% of the SCR levels measured at Week 0 (R0) of the run-in period.

Exclusion criteria

Patients were excluded if they met any of the following criteria.

At the time of pre-registration:
1. Patients with secondary glomerular disease associated with lupus nephritis, hereditary nephritis (Alport syndrome), or other diseases.
2. Patients with chronic renal failure associated with primary pyelonephritis, primary tubulointerstitial nephritis, primary glomerulonephritis, primary gout nephropathy, primary cystic kidney disease, or primary nephropathies/arteriosclerosis.
3. Patients with diabetes mellitus.
4. Patients with a history of renal transplantation, hemodialysis, or continuous ambulatory peritoneal dialysis (CAPD).
5. Patients with a comorbid urinary tract infection.
6. Patients with comorbid nephritic syndrome.
7. Patients who experienced chronic bleeding (from hemophilia, capillary fragility, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, frenal hemorrhage, and other causes), or those patients with bleeding tendency, with the exception of transient bleeding, such as epistaxis/nasal bleeding, menorrhagia bleeding, gingival bleeding, and hemorrhoidal bleeding.
8. Patients suffering from malignant hypertension or poorly-controlled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥95 mmHg at rest, measured at all three evaluation points immediately before obtaining consent).
9. Patients with comorbid malignancy.
10. Patients suffering from severe hepatic diseases, hematologic diseases, respiratory diseases, digestive system diseases, cardiac diseases, or amyloidosis.
11. Patients who experienced allergic reactions to BPS.
12. Patients who had taken another investigational drug or a post-marketing study drug within the six months before obtaining consent.
13. Patients who were pregnant, nursing, or those who wished to become pregnant during the study period.
14. Patients who had a history of illicit drug or alcohol abuse.
15. Patients who exhibited poor self-management behaviors, such as those involving diet and medication.
16. Other patients who were determined by the principal investigator or a sub-investigator as being unsuitable for participating in the study.

At the time of registration, measures were taken to ensure that none of the patients met any of the exclusion criteria (1) through (16) that were set at pre-registration. At the time of registration, however, the exclusion criteria (3) and (8) set at pre-registration were revised as follows:
3. Patients with comorbid diabetes mellitus or those with ICDAC levels of 6.5% or higher.
8. Patients suffering from malignant hypertension or poorly-controlled hypertension (systolic blood pressure ≥145 mmHg or diastolic blood pressure ≥95 mmHg measured while the patient is sitting at rest). The measurements must be consistent at all three consecutive evaluation points during the run-in period.)
administered twice daily for 22 weeks in a single-blinded manner, patients who met all of the inclusion criteria and none of the exclusion criteria (detailed in Fig. 2) were randomized into one of the three treatment groups (TRK-100STP 120 μg, 240 μg or placebo group) using computer random number generator to select random permuted blocks. Central randomization was performed by external statistician for the 28-week treatment period in a double-blinded manner. Enrollment to the trial was restricted to patients whose renal function had progressively declined during the 22-week run-in period (R0 ~ R20) to obtain adequate treatment response data during the 28-week treatment period (W0 ~ W28).

Reciprocal of serum creatinine (1/SCr) versus time slope shows the speed of renal function decline so that this parameter is used to estimate how long it will take to start dialysis and to evaluate therapeutic effects [38]. This parameter is used for example to show the status of nephropathy in the RENAAL trial [39].

Therefore, in order to limit the participants to those with progressive diseases, only patients whose reciprocal of serum creatinine (1/SCr) versus time slope was ≤ −0.005 dL/mg over 4 weeks during the run-in period were randomized. This value was based on the patients’ background in a trial of orally administered spherical carbon adsorbent AST-120 [40]. The primary endpoint was also 1/SCr versus time slope and the differences between the treatment- and the observation-period values were evaluated.

The study drug in the treatment period was orally administered twice daily, after meals, for 28 weeks in a double-blinded manner. The first 2 weeks of the treatment period were designated as the dose-titration period with respect to safety analyses. The initial dose for the TRK-100STP groups was 120 μg/day. For the 240 μg group, the dose was increased to 240 μg/day after the 2-week dose-titration period. One follow-up assessment was performed between 7 to 35 days after completion or discontinuation of study drug during the treatment period.

The two doses of TRK-100STP (120 μg/day and 240 μg/day) were selected for this trial on the basis that a 30 μg single dose was considered unable to achieve the effective plasma concentration, whilst a 180 μg single dose previously resulted in a higher incidence of headache and other adverse drug reactions (ADRs) in a completed phase I clinical study of TRK-100STP. Based on these observations, TRK-100STP at 60 to 120 μg b.i.d. (i.e., 120 to 240 μg/day) were selected for investigation in the present trial.

**Table 1** Study measurements

| Examination by investigator | Objective symptoms (patient interview) |
|----------------------------|----------------------------------------|
| Physical examination       | Body weight, blood pressure, pulse rate, 12-lead ECG |
| Hematological examination  | WBC, RBC, Hb, Ht, PLT, Differential count of leukocytes (basophil, eosinophil, neutrophil, lymphocyte, monocyte) |
| Bleeding and coagulation test | PT, APTT |
| Blood biochemistry         | TP, Alb, T-BIL, AST(GOT), ALT(GPT), ALP, LDH, γ-GTP, TCh, TG, UA, BUN, serum creatinine (SCr), Na, K, Cl, Ca, P, HbA1c, cystatin C, High-sensitive CRP |
| Uremia toxins test in plasma | Guanidino succinate |
| Urinalysis (occasional urine) | pH, qualitative protein, glucose, and urobilinogen, occult blood reaction urinary sediment (RBC, WBC, casts), β2 microglobulin (adjusted by creatinine), pregnancy test (hCG) |
| Urinalysis (24-hour pooled urine) | Urinary protein excretion, CCR, urea nitrogen, electrolytes (Na, Cl), urine output, creatinine |
Fig. 3 (See legend on next page.)

Informed consent obtained
n = 431

Pre-registered
n = 420

Ineligible for pre-registration
n = 11

Began the run-in period
n = 391

Dropped out before the run-in period: n = 29
(Reasons)
- Consent withdrawal: n = 11
- Protocol deviations: n = 6
- Unfavorable medical events: n = 5
- Not meeting inclusion/exclusion criteria: n = 3
- Follow-up unable to continue: n = 1
- Other reasons: n = 3

Registration
n = 113

Dropped out during the run-in period:
 n = 278*
(Reasons)
- Not meeting inclusion/exclusion criteria: n = 238
- Adverse event: n = 12
- Consent withdrawal: n = 11
- Target disease exacerbation: n = 4
- Protocol deviations: n = 3
- Death: n = 2
- Other reasons: n = 8

Study treatment
n = 112
(Safety analysis set)

Excluded before initiation of study treatment: n = 1
(Reason)
- Protocol deviation
(Mistakenly took the Run-in period medication after registration)

120 µg group**
n = 36

240 µg group**
n = 41

Placebo group**
n = 35

Discontinued study treatment: n = 8
(Reasons***)
- Adverse event: n = 3
- Protocol deviations: n = 3
- Target disease exacerbation (side effect): n = 1
- Not meeting inclusion/exclusion criteria: n = 1

Completed
n = 28

Discontinued study treatment: n = 7
(Reasons***)
- Adverse event: n = 6
- Unsatisfactory response: n = 1

Completed
n = 34

Discontinued study treatment: n = 3
(Reasons***)
- Protocol deviation: n=1
- Unsatisfactory response: n=1
- Target disease exacerbation: n=1

Completed
n = 32
anallogues, other than eye drops and those in ointment form; antiplatelet agents, with the exception of aspirin products; anticoagulant and thrombolytic agents, except for temporary use such as for examinations; fluorinated pyrimidine antifungal agents; and iodinated radiocontrast agents.

Restricted concomitant medications
Dosage of ACEIs and ARBs were stipulated to be fixed during the study period. However, in necessary situations, such as increased serum potassium levels that did not improve with alternative options, a reduction in ACEI or ARB doses was allowed. Taking nonsteroidal anti-inflammatory drugs (NSAIDs) continuously for more than one week was prohibited.

Sample size estimation
The sample size estimation was based on a previous study, a Phase III clinical trial of AST-120 (indicated for the treatment of chronic renal failure (CRF) in Japan), conducted in a total of 237 patients (119 patients treated with the active drug and 118 received placebo) for 24 weeks [40]. The study showed that the difference in the slope of regression line of 1/SCr versus time of AST-120 and the placebo groups before and after treatment with the test drug was 0.00352 (dL/mg over 4 weeks). Based on this value, we hypothesized that the TRK-100STP 120 μg group would show efficacy similar to the AST-120 group, and that the TRK-100STP 240 μg group would show 1.5 times better efficacy than the AST-120 group. According to these predictions, we set contrast coefficients \([-1, 0, 1]\) for the placebo, the TRK-100STP 120 μg, and the 240 μg groups. The number of patients required per group was estimated to be 71 (with a two-sided 5 % significance level and 80 % statistical power). On this basis, the target number of patients needed to recruit was set at 430 patients, taking into account the possibility that the patient withdrawal rate in the run-in period might be high because of the long run-in period.

Table 2 Baseline characteristics of patients in the full analysis set (FAS)

| Parameter                                      | Treatment group |
|------------------------------------------------|-----------------|
|                                                 | Placebo (n = 34) | 120 μg (n = 32) | 240 μg (n = 36) |
| Sex                                            | Male            | 18 (52.9 %)     | 17 (53.1 %)     | 24 (66.7 %)  |
|                                                | Female          | 16 (47.1 %)     | 15 (46.9 %)     | 12 (33.3 %)  |
| Age                                            | Mean ± SD (years) | 59.9 ± 10.0    | 56.5 ± 14.7    | 57.8 ± 13.9  |
| Primary disease                                | Primary glomerular disease | 28 (82.4 %) | 27 (84.4 %) | 25 (69.4 %) |
|                                                | Nephrosclerosis  | 6 (17.6 %)      | 5 (15.6 %)     | 11 (30.6 %)  |
| 1/SCr time slope during the run-in period      | Mean ± SD (dL/mg over 4 weeks) | −0.01210 ± 0.00497 | −0.01535 ± 0.00808 | −0.01198 ± 0.00788 |
| SCRa                                          | Mean ± SD (mg/dL) | 2.377 ± 0.665  | 2.251 ± 0.618  | 2.564 ± 0.705 |
| Urinary protein excretiona                     | Mean ± SD (mg/day) | 2103.7 ± 1523.0 | 2037.5 ± 1763.4 | 1753.9 ± 1396.2 |
| Systolic blood pressurea                        | Mean ± SD (mmHg) | 122.7 ± 16.1    | 129.0 ± 13.3   | 129.4 ± 15.6  |
| Diastolic blood pressurea                       | Mean ± SD (mmHg) | 72.5 ± 11.0     | 73.4 ± 10.3    | 75.1 ± 10.6   |
| Concomitant medication                         | ACEI (+)        | 13 (38.2 %)     | 9 (28.1 %)     | 12 (33.3 %)   |
|                                                | ARB (+)         | 25 (73.5 %)     | 26 (81.3 %)    | 25 (69.4 %)   |

*aAs of R20

Statistical analysis
(a) Primary endpoint
Using all SCr data collected during the run-in period (R0 ~ R20) and treatment period (W4 ~ W28), reciprocal SCr values plotted against time were analyzed. The slopes of the regression line were calculated by applying the least-squares equation. The difference in the slopes between the run-in period (R0 ~ R20) and treatment period (W4 ~ W28) was evaluated as the primary endpoint. In order to determine the recommended dose,
the primary endpoint was analyzed by the following procedures:

- **Step 1:** Analysis of covariance (ANCOVA) with the slopes calculated from the results obtained during the run-in period as a covariate after assigning contrast coefficients \([-1, 0, 1]\).
- **Step 2:** ANCOVA with the slopes obtained from the results collected during the run-in period as a covariate after assigning contrast coefficient \([-1, 1, 0]\), only when a statistical significance was detected in Step 1.

(b) Secondary endpoints
Analytical methods for secondary endpoints are described in each result.

(c) Post hoc analysis
**Ratio of SCr (the final evaluation point/W0)**
In analyzing the ratio of SCr for the secondary endpoint, the SCr values measured at R20 were chosen as baseline as other parameters such as CCr, urinary protein and cystatin C were measured only at R20. Regarding SCr, however, as the value at W0 measured just before the treatment period was available, the ratio of SCr (the final evaluation point/W0) was assessed by ANCOVA with the SCr (R20) as covariate.

**Change in serum cystatin C in the treatment period (final evaluation point - R20)**
As the ratio of SCr was analyzed only for the treatment period, changes in cystatin C were re-evaluated based only on data from the treatment period.

Changes in cystatin C were calculated using values taken at R20 as the baseline (the final evaluation point – R20). ANCOVA was performed with the SCr (R20) as the covariate. As the values at W0 were not available, the values at R20, the examination point of the study closest to W0, were used as baseline.

**Ratio of eGFR (the final evaluation point/W0)**
Ratio of eGFR (the final evaluation point/W0) was assessed by ANCOVA with the SCr (R20) as covariate. In order to calculate the eGFR for Japanese patients, the following equation was used:

\[
GFR_{(male)} = 194 \times \text{Scr}^{-1.094} \times \text{age}^{-0.287} \text{, and GFR}_{(female)} = GFR_{(male)} \times 0.739 \] [41].

**Study measurements**
The parameters that were measured and analyzed are listed in Table 1.

| Treatment group | No. of patients | 1/SCr versus time slope (dL/mg over 4 weeks) | Difference in the 1/SCr versus time slope (dL/mg over 4 weeks) |
|-----------------|----------------|---------------------------------------------|---------------------------------------------------------------|
|                 |                | Run-in period (R0 ~ R20)                          | Treatment period (W4 ~ W28)                             |
|                 |                | Mean  SD                                      | Mean  SD                                      | Mean  SD                                      |
| Placebo         | 34             | −0.0121 0.00497                                | −0.0074 0.00935                                    | 0.0047 0.01087                                |
| 120 µg          | 32             | −0.0154 0.00808                                | −0.0040 0.01345                                    | 0.0113 0.01011                                |
| 240 µg          | 36             | −0.0120 0.00788                                | −0.0045 0.00750                                    | 0.0075 0.00953                                |
Trial registration
NCT02480751. June 21, 2015.

Results
Patient disposition
The trial began on October 24, 2005 (the date the first consent was obtained) and was completed on May 20, 2008 (the last follow-up date of the final patient).

A summary of the patient disposition is described in Fig. 3. Written informed consents were obtained from a total of 431 patients, 11 of whom did not meet the criteria on pre-registration and a total of 420 patients were pre-registered. Of these 420 patients, 29 dropped out before the start of the run-in period and a further 278 patients were withdrawn during the run-in period or at the registration. A total of 113 patients were therefore registered, of which one patient, who mistakenly took the run-in period medication and did not take the study drug for the treatment period after the registration, was excluded from the study. As a result, the study drugs were administered to a final total of 112 patients (35 patients in the placebo group, 32 patients in the 120 μg group and 36 patients in the 240 μg group) in a double-blind manner. Most of 238 patients who did not meet the inclusion/exclusion criteria before registration were excluded because their renal failure progressed at a slower rate during the run-in period, represented by a 1/SCr versus time slope of ≤−0.005 dL/mg over 4 weeks.

Analysis sets
Ten patients whose SCr values measured less than three points after Week 4 of the treatment period were excluded from 112 patients randomized. As a result, 102 patients (34 patients in the placebo group, 32 patients in the 120 μg group and 36 patients in the 240 μg group) were included in the full analysis set (FAS). From FAS, four patients were excluded whose SCr values measured after Week 4 of the treatment period were less than 5 points. The remaining patients constituted the per protocol set (PPS). PPS therefore consisted of 98 patients (34 patients in the placebo group, 29 patients in the 120 μg group and 35 patients in the 240 μg group). The safety analysis set consisted of 112 patients (35 patients in the placebo group, 36 patients in the 120 μg group and 41 patients in the 240 μg group), who received the study drug for the treatment period.

Demographic and other baseline characteristics of patients in the FAS are presented in Table 2. Baseline characteristics of patients were not significantly different.

Table 4 Difference in the 1/SCr versus time slope between run-in period (R0 ~ R20), and Treatment period (W4 ~ W28) analyzed by the ANCOVA model: comparison of the TRK-100STP groups versus placebo

| Treatment group | No. of patients | Least square mean of the change in the 1/SCr slope | Difference in the least square mean (versus placebo) | Contrast test (P value) |
|-----------------|-----------------|------------------------------------------|---------------------------------|----------------------|
|                 |                 | Point estimate | 95 % CI               | Point estimate | 95 % CI | (−1,0,1) |
| Placebo        | 34              | 0.00516        | [0.00187, 0.00845]     | —              | —       | —        |
| 120 μg          | 32              | 0.01026        | [0.00682, 0.01369]     | 0.00510        | [0.00031, 0.00989] | 0.2234   |
| 240 μg          | 36              | 0.00798        | [0.00478, 0.01118]     | 0.00282        | [−0.00175, 0.00740] | —        |

*120 μg group or 240 μg group – (placebo group)
1/SCr versus time slope during the run-in period as the covariate.
among the treatment groups. It is noteworthy that 69% to 81% of patients were taking ARB in each group.

Changes in SCR

Figure 4 illustrates the changes in SCR through the study periods when SCR values of each group at R20 were set at 100%. The SCR values in all three groups increased during the run-in and treatment periods, and increases in SCR values in the treatment period tend to be suppressed in the two TRK-100STP groups.

Efficacy

As the primary analysis set is also the FAS, the data and the results of evaluation are described based on the FAS, whilst the efficacy analysis was performed in both the FAS and PPS.

(a) Primary endpoint

The difference in the $1/\text{SCR}$ versus time slope between the run-in period ($R0 \sim R20$) and the treatment period ($W4 \sim W28$)

As shown in Table 3 and Fig. 5, compared with the run-in period, a slight improvement in the $1/\text{SCR}$ versus time slope was observed during the treatment period in all treatment groups; this tendency was clearly observed in patients of the TRK-100STP 120 μg group.

Table 4 shows the result of ANCOVA with the $1/\text{SCR}$ versus time slope during the run-in period as the covariate. No statistically significant difference was observed between the 240 μg group and the placebo group when the ANCOVA was performed with the contrast coefficients of $[-1, 0, 1]$ for [the placebo group, the 120 μg group, and the 240 μg group] ($P = 0.2234$).

(b) Secondary endpoints

The difference in the $1/\text{SCR}$ versus time slope between the run-in period ($R0 \sim R20$) and the treatment period ($W0 \sim W28$)

The least square mean of the difference in the $1/\text{SCR}$ versus time slope [95% CI] was 0.00590 dL/mg over 4 weeks [0.00308, 0.00873] in the placebo group, 0.01065 dL/mg over 4 weeks [0.00769, 0.01360] in the TRK-100STP 120 μg group and 0.00801 dL/mg over 4 weeks [0.00525, 0.01076] in the 240 μg group. Moreover, ANCOVA was performed on the same model as the primary endpoint with the contrast coefficients of $[-1, 0, 1]$ and $[-2, 1, 1]$ for the placebo group, the 120 μg group, and the 240 μg group respectively. The results of ANCOVA with contrast coefficients of $[-1, 0, 1], [-1, 1, 0], [-1, -1, 2], [-2, 1, 1]$ were $P = 0.2912$, $P = 0.0244$, $P = 0.8764$ and $P = 0.0534$, respectively. Thus the 120 μg

Table 5 Ratio of SCR (the final evaluation point/W0 [week 0 of the treatment period]) analyzed by the ANCOVA model

| Treatment group | Number of patients | Least square mean of the ratio of SCR | Difference in the least square mean (versus placebo) | P-value* |
|-----------------|--------------------|--------------------------------------|-----------------------------------------------------|----------|
|                 |                    | Point estimate | SE | Point estimate | SE |----------|
| Placebo         | 34                 | 1.169        | 0.032 | –         | –         | –        |
| 120 μg          | 32                 | 1.069        | 0.033 | 0.100     | 0.045     | 0.0309   |
| 240 μg          | 36                 | 1.064        | 0.031 | 0.105     | 0.044     | 0.0204   |

*At Week 28 of the treatment period or when treatment was discontinued
*ANCOVA with baseline (SCR(R20)) as covariate

![Fig. 6 Mean ± SD of ratio of SCR (final evaluation point/W0 [week 0 of the treatment period]): As shown in Table 5, both the 120 μg and the 240 μg groups showed an inhibition of the increase in SCR ratios as compared with the placebo group ($P = 0.0309, 0.0204$, respectively), assessed by ANCOVA with the SCR (R20) as covariate]
group showed a significant amelioration compared with the placebo group (contrast coefficients: $[-1, 1, 0]$: $P = 0.0244$).

### Changes in $\text{CCR}$

The difference in the change of $\text{CCR}$ in urinalysis with 24-hour pooled urine sample (the change in the treatment period [the final evaluation point – R20]) was $1.08 \pm 9.35$ mL/min in the placebo group (mean ± SD), $6.16 \pm 11.22$ mL/min in the TRK-100STP 120 µg group and $3.94 \pm 7.80$ mL/min in the 240 µg group. Both TRK-100STP groups therefore showed a tendency of inhibiting the decline in $\text{CCR}$ as compared with the placebo group ($P = 0.0551$, $P = 0.1800$: t-test). When $\text{CCR}$ was calculated with the Cockcroft-Gault equation, the change in the treatment period (the final evaluation point – R20) was $2.03 \pm 5.98$ mL/min in the placebo group (mean ± SD), $3.93 \pm 5.30$ mL/min in the TRK-100STP 120 µg group and $3.77 \pm 5.06$ mL/min in the 240 µg group. Both TRK-100STP groups therefore showed a tendency of inhibiting the decline in $\text{CCR}$ as compared with the placebo group ($P = 0.1771$, $P = 0.1917$: t-test).

### Changes in urinary protein excretion

The change in urinary protein excretion (the final evaluation point – R20) was $121.59 \pm 715.60$ mg/day in the placebo group, $241.68 \pm 849.23$ mg/day in the TRK-100STP 120 µg group and $280.38 \pm 817.97$ mg/day in the 240 µg group. It was shown that the observed change in the urinary protein excretion in the 120 µg and 240 µg groups (versus the placebo group) was small relative to the standard deviation, and both TRK-100STP groups showed no significant difference compared to the placebo group ($P = 0.5457$, $P = 0.4056$: t-test).

### Ratio of $\text{SCr}$

The ratio of $\text{SCr}$ (the final evaluation point/R20) was $1.14 \pm 0.27$ in the placebo group, $1.06 \pm 0.20$ in the TRK-100STP 120 µg group and $1.06 \pm 0.13$ in the 240 µg group. Although both TRK-100STP groups did not show any significant inhibition, they showed a tendency of inhibiting the increase in $\text{SCr}$ as compared with the placebo group ($P = 0.1379$, $P = 0.0942$: t-test).

### Changes in serum cystatin C

The difference in the change in serum cystatin C (the change in the treatment period [the final evaluation point – R20] – the change in the Run-in period [R20 – R0]) was $0.155 \pm 0.448$ mg/L in the placebo group, $0.006 \pm 0.377$ mg/L in the TRK-100STP 120 µg group, and $-0.023 \pm 0.645$ mg/L in the 240 µg group. Both TRK-100STP groups therefore showed a tendency of inhibiting the increase in serum cystatin C as compared versus the placebo group ($P = 0.1588$, $P = 0.1973$: t-test).

---

**Table 6** Changes in serum cystatin C (the final evaluation point–R20 (week 20 of the Run-in period)) comparison of TRK-100STP groups versus placebo analyzed by the ANCOVA model

| Treatment group | Number of patients | Least square mean of the difference in serum cystatin C (mg/L) | Difference in the least square mean (versus placebo) (mg/L) | P-value |
|-----------------|-------------------|-------------------------------------------------------------|------------------------------------------------|----------|
|                 |                   | Point estimate | SE | Point estimate | SE |                  |
| Placebo         | 32                | 0.253          | 0.065 | — | — | — |
| 120 µg          | 31                | 0.097          | 0.066 | 0.157 | 0.092 | 0.0928 |
| 240 µg          | 35                | 0.052          | 0.063 | 0.201 | 0.090 | 0.0285 |

*At Week 28 of the treatment period or when treatment was discontinued

Different from FAS because some patients lacked value of cystatin C

---

**Fig. 7** Mean ± SD of changes in serum cystatin C (final evaluation point – R20): As shown in Table 6, the 120 µg group showed a tendency and the 240 µg group showed significant inhibition of the increase in serum cystatin C as compared with the placebo group ($P = 0.0928$, 0.0285, respectively), assessed by ANCOVA with the $\text{Scr}$ (R20) as covariate.
Table 7 Change in eGFR [the final evaluation point/W0 (week 0 of the treatment period)] analyzed by the ANCOVA model

| Treatment group | Number of patients | Least square mean of the difference in serum cystatin C (mg/L) | Difference in the least square mean (versus placebo) (mg/L) | P-value |
|-----------------|--------------------|-------------------------------------------------------------|-------------------------------------------------------------|---------|
|                 |                    | Point estimate | SE | Point estimate | SE |         |         |
| Placebo         | 34                 | 0.877       | 0.025 | —            | —  | —       | —       |
| 120 µg          | 32                 | 0.952       | 0.026 | 0.075        | 0.036 | 0.0365  |         |
| 240 µg          | 36                 | 0.942       | 0.024 | 0.065        | 0.035 | 0.0628  |         |

*At Week 28 of the treatment period or when treatment was discontinued

(c) Post hoc analysis

Ratio of SCr (final evaluation point/W0)

As shown in Table 5 and Fig. 6, both the 120 µg and the 240 µg groups showed a significant inhibition of the increase in SCr ratios as compared with the placebo group.

Change in serum cystatin C in treatment period (final evaluation point – R20)

As shown in Table 6 and Fig. 7, the 120 µg group showed a tendency and the 240 µg groups showed significant inhibition of the increase in change in serum cystatin C as compared with the placebo group.

Ratio of eGFR

As shown in Table 7, the 240 µg group showed a tendency and the 120 µg groups showed significant inhibition of the decrease in eGFR ratios as compared with the placebo group.

Safety and tolerability

The safety analysis was conducted based on any AEs reported during the study period. The incidence of AEs are summarized in Table 8. Two death were observed in this study; they occurred during the run-in period and so any causal relationships with the study drug was excluded.

The incidence of ADRs are summarized in Table 9. All of these ADRs cases were mild to moderate in severity, and recovered without treatment. Two serious adverse drug reactions (SADR) of cardiac failure and acute myocardial infarction were observed in the 120 µg group after randomization and both patients recovered.

The AEs and ADRs that occurred at an incidence of 5% or more are summarized in Table 10. The severity of headache in ADR was as follows: moderate headache was reported in 1 patient in the 240 µg group; mild headache was reported in 1 patient in the 120 µg group, and 5 patients in the 240 µg group. All of these patients recovered without treatment. For clinical laboratory tests, vital signs, body weight and 12-lead ECG, no specific concerns were observed. TRK-100STP did not have significant effect on blood pressure at any dose, as detailed in Table 11.

Discussion

This is the first randomized, double-blind, placebo controlled comparative trial of TRK-100STP to investigate the possible therapeutic dose of TRK-100STP in CKD patients with a primary disease of glomerular disease or nephrosclerosis.

In the FAS, statistical superiority of the 240 µg group over the placebo could not be confirmed by the primary endpoint, and so the putative recommended dose could not be clearly determined. One of the reasons why statistically significant superiority could not be confirmed was the trial lost statistical power due to the fact that more patients than had been expected were withdrawn from the study during the run-in period. As we needed to consider the feasibility of study completion, we could not secure the sufficient number of patients for analysis.

This is considered to be because the pace at which the decline in renal function became slower during the run-in period. As shown in Table 3, 1/SCr versus time slope in the treatment period was ameliorated even in the placebo group. In this trial, the CKD patients who progressed and whose 1/SCr versus time slopes were ≤ −0.005 dL/mg over 4 weeks were selected at the start of the treatment period. As a result, the number of patients to be enrolled was reduced to about 1/3 of patients who had been screened. It is thought that such selection of patients also led to the regression toward the mean in all groups. This amelioration in the 1/SCr versus time slope in the placebo group may have made it difficult to detect the difference between the placebo group and the 240 µg group in terms of the primary endpoint. However, our trial showed, for the first time, that TRK-100STP might prevent the decline of renal function.

Table 8 Summary of the incidence of adverse events

| Parameter                                                   | 120 µg     | 240 µg     | Placebo    |
|-------------------------------------------------------------|------------|------------|------------|
| Number of patients evaluated                                | 36         | 41         | 35         |
| Number of patients who experienced adverse events           | 27 (75.0 %)| 36 (87.8 %)| 28 (80.0 %)|
| Number of patients who experienced serious adverse events  | 3 (8.3 %)  | 4 (9.8 %)  | 1 (2.9 %)  |
| Number of patients who discontinued the study treatment due to adverse events | 4 (11.1 %) | 7 (17.1 %) | 0 (0.0 %)  |

*: Incidence rate
This conclusion was supported by the following facts: both active study drug treatment groups exhibited better efficacy than the placebo group, and the efficacy was particularly high in the 120 μg group on the primary endpoint. In the secondary endpoint analysis, both TRK-100STP groups showed improvements on each of the renal filtration function parameters evaluated (1/SCr versus time slope, change in the CCr, ratio of SCr, and change in serum cystatin C). Among them, a significant improvement was observed in the slope for 1/SCr versus time when contrast coefficients [−1, 1, 0] were used, suggesting a valid hypothesis that the improvement in 120 μg group was remarkable. In addition, in the post-hoc analysis, a significant improvement in the ratio of SCr was achieved in the 120 μg group as well as in the 240 μg group. The difference in cystatin C levels in the treatment period also improved in the 240 μg group. Regarding the eGFR ratio, a significant improvement was observed only in the 120 μg group.

Significant effects on blood pressure or urinary protein levels were not observed in this study, and thus the mechanisms of action of BPS are thought to be different from those of existing agents such as ACEIs and ARBs. Since the majority of patients in this study was taking ACEIs and/or ARBs, TRK-100STP may be a useful for treatment of CKD patients in combination with ACEIs or ARBs. TRK-100STP was considered to be well tolerated. Most of the AEs observed in this study were similar types of the events caused by prostacyclin and its analogue.

Several important limitations to this study are apparent: as the treatment period was comparatively short (28 weeks) for evaluating the decrease in the renal function, the enrollment to the trial was restricted to those patients whose renal function had progressively declined. In addition, no dialysis or doubling of SCr was observed during the study period so that its efficacy on the renal composite endpoint including dialysis was unclear. Further evaluation in a longer study period will therefore be necessary in future.

Based on the findings of this trial, we have further been conducting a phase IIb/III trial, CASSIOPEIR (CRF Asian Study with Oral PGl2 derivative for Evaluating Improvement of Renal function) [42]. This new trial will enroll patients who have more severe disease than those enrolled in this trial in order to ensure that a sufficient

Table 9 Summary of adverse drug reaction incidence

| Parameter                                      | 120 μg | 240 μg | Placebo |
|------------------------------------------------|--------|--------|---------|
| Number of patients evaluated                   | 36     | 41     | 35      |
| Number of patients who experienced ADR         | 7 (19.4 %) | 13 (31.7 %) | 5 (14.3 %) |
| Number of patients who experienced serious ADR | 2 (5.6 %) | 0 (0.0 %) | 0 (0.0 %) |
| Number of patients who discontinued the study treatment due to ADR | 3 (8.3 %) | 5 (12.2 %) | 0 (0.0 %) |
| Number of patients who interrupted the study treatment due to ADR | 0 (0.0 %) | 1 (2.4 %) | 0 (0.0 %) |

: Incidence rate

Table 10 Adverse events and adverse drug reactions with an incidence of 5 % or more

| Adverse Events                          | 120 μg | 240 μg | Placebo |
|-----------------------------------------|--------|--------|---------|
| 120 μg                                  |        |        |         |
| Headache                                | 5 (13.9 %) | 11 (26.8 %) | 8 (22.9 %) |
| Nasopharyngitis                         | 4 (11.1 %) | 7 (17.1 %) | 3 (8.6 %) |
| Back pain                               | 3 (8.3 %) | 5 (12.2 %) | 3 (8.6 %) |
| Hyperkalemia                            | 2 (5.6 %) | 3 (7.3 %) | 3 (8.6 %) |
| Dizziness                               | 2 (5.6 %) | 3 (7.3 %) | 3 (8.6 %) |
| Hypertension                            | 2 (5.6 %) | 3 (7.3 %) | 3 (8.6 %) |
| Upper respiratory tract inflammation    | 2 (5.6 %) | 3 (7.3 %) | 3 (8.6 %) |
| Diarrhea                                | 2 (5.6 %) | 3 (7.3 %) | 3 (8.6 %) |
| Vomiting                                | 2 (5.6 %) | 3 (7.3 %) | 3 (8.6 %) |
| Arthralgia                              | 2 (5.6 %) | 3 (7.3 %) | 3 (8.6 %) |
| Adverse drug reactions                   |        |        |         |
| 120 μg                                  |        |        |         |
| Hypertension                            | 2 (5.6 %) | 6 (14.6 %) | 2 (5.7 %) |
| Placebo                                 |        |        |         |
| Malaise                                 | 3 (7.3 %) | 3 (7.3 %) | 3 (7.3 %) |

: Incidence rate
number of clinical events can be observed within a designated time period, using renal composite endpoints to evaluate treatment outcome. This trial will also be dose-finding as it utilizes the same two doses as used in this study. The trial is being conducted in seven Asian countries, including Japan.

Conclusions
Although this randomized, placebo-controlled, double-blind, comparative trial failed to meet the primary endpoint to determine the recommended dose for the treatment of patients with CKD with primary glomerular disease or nephrosclerosis, it shows for the first time, that TRK-100STP might potentially prevent the decline in renal function of such patients, independent of blood pressure or urinary protein levels. These findings have helped in the design and conduct of the ongoing phase IIb/III trial, CASSIOPEIR.

Additional file

Additional file 1: CONSORT 2010 Flow Diagram. (DOC 37 kb)

Abbreviations
ACEs: Angiotensin-converting enzyme inhibitors; ADR: Adverse drug reaction; AE: Adverse event; ANCOVA: Analysis of covariance; ARB: Angiotensin-II receptor blocker; BPS: Beraprost sodium; CASSIOPEIR: GIF Asian Study with Oral PGI derivative for Evaluating Improvement of Renal function; CG: Creatinine clearance; CKD: Chronic kidney disease; CRF: Chronic renal failure; ECG: Electrocardiogram; ESRD: End-stage renal disease; FAS: Full analysis set; NSAIDs: Nonsteroidal anti-inflammatory drugs; PGI: Prostacyclin); PPS: Per protocol set; RAS: Renin-angiotensin system; SADR: Serious adverse drug reactions; SCr: Serum creatinine.

Competing interests
AK and FG have no conflict of interest. TF and HO serve as a consultant of Toray. AK, TF and FG were assigned as medical advisors for the study but their participation and assistance in the trial. We would like to thank Midori Ogasawara and Satoshi Henni of Toray, Hiroshi Kakuta, Tomohisa Kawasaki and Hiroyuki Okumura of Astellas and Jun Kishi of MEDCORE ASSOCIATES Inc., for having provided their assistance in the preparation of the report.

Acknowledgements
This trial was sponsored by Toray Industries, Inc. and Astellas Pharma Inc. in the design, and in the collection and analysis of the data.

We would like to thank the doctors, nurses and staff at the sites listed below for their participation and assistance in the trial. We also thank Osamu Hotta and Takayuki Fujita for their important suggestion about the design of the protocol and thank Yoshitaka Morai, Takeshi Matsugi, and all other members of Toray and Astellas for the participation in the trial. We would like to thank Midori Ogasawara and Satoshi Henni of Toray, Hiroshi Kakuta, Tomohisa Kawasaki and Hiroyuki Okumura of Astellas and Jun Kishi of MEDCORE ASSOCIATES Inc., for having provided their assistance in the preparation of the report.

Participating centers
Aizawa Hospital, Akebono Hospital, Anjo Kosei Hospital, Asahi Chuo Hospital, Chiba Seikatsu-shukanbyo Internal Medicine Clinic, Chubu Rosai Hospital, Dainihara Medical Clinic, Fujiwara City Hospital, Fujita Health University Hospital, Fukuoka University Hospital, Hamamatsu University Hospital, Hiroshima City Hospital, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hitachi General Hospital, Hitachi Mito General Hospital, Hokkaido University Hospital, Ichikawa East Hospital, Japanese Red Cross Society Suwa Hospital, Jichi Medical University Hospital, Kasugai Municipal Hospital, Kawahara Clinic, Kawasaki Medical School Hospital, Kawashima Clinic, Kizumaki Hospital, Kinki University Hospital, Kitasato Hospital, Kyosai Hospital, Toho University Omori Medical Center, Tokai University Hospital, Tottori University Hospital, Toyama General Medical Center, Tokuyama Central Hospital, Tottori University Hospital, Toho University Omori Medical Center, Tokai University Hospital, Toho University Omori Medical Center, Toyama General Medical Center, Tokuyama Central Hospital, Tokyo Kyosai Hospital, Tokyo Medical

Table 11 Effect of TRK-100STP 120 µg and 240 µg on blood pressure

| Treatment group | Systolic blood pressure | Diastolic blood pressure |
|-----------------|-------------------------|-------------------------|
|                 | R20 | Final evaluation point | R20 | Final evaluation point |
| Placebo         |     |                       |     |                       |
| No. of patients | 35  | 35                     | 35  | 35                     |
| Mean ± SD      | 123.8 ± 17.0             | 127.5 ± 20.3            | 72.7 ± 10.9 | 75.3 ± 9.9 |
| 120 µg         |     |                       |     |                       |
| No. of patients | 36  | 35                     | 36  | 35                     |
| Mean ± SD      | 128.3 ± 13.0             | 127.8 ± 13.5            | 73.6 ± 10.7 | 75.4 ± 10.5 |
| 240 µg         |     |                       |     |                       |
| No. of patients | 41  | 40                     | 41  | 40                     |
| Mean ± SD      | 128.3 ± 16.4             | 129.4 ± 13.7            | 74.4 ± 10.6 | 75.1 ± 8.9 |

(Unit of blood pressure: mmHg)
University Hospital, Tokyo Medical University Ibaraki Medical Center, Tosei General Hospital, Toyota Memorial Hospital, Tsuchiya General Hospital, Tsukuba Central Hospital, Tsukuba University Hospital, Ureshino Medical Center, Yokohama City Minato Red Cross Hospital, Yokohama City University Medical Center, Yokohama Minami Kyousai Hospital, Yonago Medical Center.

Author details
1University of Tsukuba, 1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan.
2Division of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan.
3Division of Biostatistics and Clinical Epidemiology, Graduate School of Medicine and Pharmaceutical Sciences, The University of Toyama, 2630 Sugitani, Toyama City 930-0194, Japan.
4Toray Industries, Inc., 1-1, Nihonbashi-Muramachi 2-chome, Chuo-ku, Tokyo 103-8666, Japan.
5Astellas Pharma Inc., 2-5-1 Nihonbashishoncho, Chuo-ku, Tokyo 103-8411, Japan.

Received: 23 January 2015 Accepted: 28 July 2015

References
1. Xie Y, Chen X. Epidemiology, major outcomes, risk factors, prevention and -management of chronic kidney disease in China. Am J Nephrol. 2008;28(1):7.
2. Akizawa T. Current Status of Dialysis Therapy and Related Clinical Guidelines (Alphabetical order).
3. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15 Suppl 2:3–9.
4. Jin DC. Current status of dialysis therapy in Korea. Korean J Intern Med. 2011;26:123–31.
5. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kid Int. 2013;3:1–150.
6. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
7. Imai E, Chan JC, Isu Y, Yamasaki T, Kobayashi F, Hanaeda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–86.
8. Fried LF, Emanuelne N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;368:982–903.
9. Parving HH, Brenner BM, metric of diabetes. N Engl J Med. 2013;368:982–903.
10. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663–5.
11. Yokoyama C, Yabuki T, Shimomichi M, Wada M, Hatae T, Okhawara S, et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation. 2002;106:2397–403.
12. Spargis K, Adreamides E, Demerouxi E, Koulouzoula A, Margioulas A, Pavlidis G, et al. IPROST prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2009;120:795–9.
13. Ohno K, Nagase H, Matsumoto K, Nishiyama H, Nishio S. Stereoselective synthesis of 5,6,7-trinor-4,8-inter-m-phenylene-PGJ2 derivatives and their inhibitory activities to human platelet aggregation. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:279–81.
14. Kurumatani H. Pharmacological profiles and clinical effects of oral sustained release beraprost sodium (Careload LA tablets 60 μg, Berasus LA tablets 60 μg). Nihon Yakurigaku Zasshi. 2009;133:101–11.
15. Nagaya N. Orally active prostacyclin analogue for cardiovascular disease. Int Angiol. 2010;29(2 Suppl):14–8.
16. Fine LG, Bandopadhyay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000;75:S22–6.
17. Eckardt KJ, Bernhardt WM, Weidemann A, Wannecke C, Rosenberger C, Wessener MS, et al. Role of hypoxia in the pathogenesis of renal disease. Kid Int Suppl. 2005;95:S46–S51.
18. Kng DH, Kanelis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:826–36.
19. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:27–25.
20. Inoue T, Kozawa E, Okada H, Inukai K, Watanabe S, Kikuta T, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol. 2011;22:1429–34.
21. Utsumi Y, Obara M, Kawamura T, Mitani T, Masuhashi N, Sakai O. Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue. Clin Exp Immunol. 1995;99:454–60.
22. Kushiro M, Shikata K, Sugimoto H, Shikata Y, Miyatake N, Wada J, et al. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidn Int. 1998;53:1314–20.
23. Yamada M, Sasaki R, Sato N, Suzuki M, Tamura M, Matsuura T, et al. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. Eur J Pharmacol. 2002;449:167–76.
24. Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, et al. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. Eur J Pharmacol. 2013;714:325–31.
25. Yamaguchi S, Goto Y, Sato N, Kurumatani H, Miyamoto Y, Yamada M. Beraprost sodium suppresses progression of chronic renal failure by protecting renal capillary endothelial cells and improving renal hypoxia in glomerulonephritis rats. J Am Soc Nephrol. 2013;24:1868A.
26. Goto Y, Yamaguchi S, Tamura M, Mochizuki H, Kurumatani H, Okano K, et al. A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis. Prostaglandins Other Lipid Mediat. 2014;112:16–26.
27. Mishima K, Baba A, Matsu M, Itoh Y, Oishi R. Protective effect of cyclic AMP against ischaemically-induced nephrotoxicity. Free Radic Biol Med. 2006;40:1564–77.
28. Itoh Y, Yano T, Sendo T, Oishi R. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci. 2005;97:473–88.
29. Sakai A, Yajima M, Nishio S. Cytotoxic effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci. 1990;47:711–5.
30. Tamura M, Kurumatani H, Matsuura T. Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. Prostaglandins Leukot Essent Fatty Acids. 2001;64:197–202.
31. Nishio S, Matsuura H, Kanai N. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol. 1988;47:1–10.
32. Fujita T, Fuke Y, Satomura A, Hidaka M, Ohsawa I, Endo M, et al. PGJ2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukot Essent Fatty Acids. 2001;65:223–7.
33. Iida H, Hotta O, Takuma T. Clinical efficacy of PGJ2 derivative (BPS) in patients with progressive renal disease. Jpn J Nephrol. 2003;45:276.
34. Owada A, Suda S, Hata T. Effect of long-term administration of prostaglandin I2 in incipient diabetic nephropathy. Nephron. 2002;92:788–96.
35. Wang LN, Tang Z, Shou I, Fukui M, Tomino Y. Effects of the PGJ2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nephron. 1996;72:363–43.
36. Watanabe M, Nakashima H, Mochizuki S, Aby Y, Ishiuma A, Ito K, et al. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I2 analog, beraprost sodium. Am J Nephrol. 2009;30:1–11.
37. Sato N, Kanelo M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes. 2010;59:1092–100.
38. Mitch WE, Walser M, Buffington GA, Lemann Jr J. A simple method of estimating progression of chronic renal failure. Lancet. 1976;2(7999):1326–8.

39. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–8.

40. Koide K, Koshikawa S, Yamane Y. Clinical evaluation of AST-120 on suppression of progression of chronic renal failure. Multi-center, double-blind study in comparison with placebo. Clin Eval. 1987;15:527–64.

41. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

42. Nakamoto H, Fujita T, Otogasa H, Isomoto H, Kurumatani H, Okada K, et al. A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrol. 2014;15:153.